Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

Inclusion criteria

• ✓. Participant is between 60 to 90 years of age (inclusive) at the time of consent; and
• ✓. Participant has a study partner who has sufficient and frequent contact with the participant (defined as at least 8 hours of contact a week) and is able to provide accurate information regarding the participant's cognitive and functional abilities.
• ✓. Participants must provide written consent in the IRB-approved or Ethics Committee (EC) approved informed consent form or have a legally authorized representative (LAR) provide written consent on the participant's behalf in accordance with local and national guidance and regulation;
• ✓. Participants must be willing to undergo an MRI brain scan within 90 days and an amyloid and tau PET scan within 120 days of signing informed consent;
• ✓. Participants must be willing to comply with all study procedures as outlined in the informed consent, including blood sampling, genetic testing, and storage of biospecimens for future research;
• ✓. Fluency in the language of the tests used at the study site;
• ✓. Participants must be willing to be contacted for possible participation in clinical research trials once their participation in this study ends; and
• ✓. Participants must have a Mini-Mental State Exam (MMSE) score of 16 to 30 inclusive at screening.